Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ahmed, 2015, Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma, J. Clin. Oncol., 33, 1688, 10.1200/JCO.2014.58.0225
Altvater, 2009, 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells, Clin. Cancer Res., 15, 4857, 10.1158/1078-0432.CCR-08-2810
Bachanova, 2014, NK cells in therapy of cancer, Crit. Rev. Oncog., 19, 133, 10.1615/CritRevOncog.2014011091
Bachanova, 2014, Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein, Blood, 123, 3855, 10.1182/blood-2013-10-532531
Barrett, 2014, Chimeric antigen receptor therapy for cancer, Annu. Rev. Med., 65, 333, 10.1146/annurev-med-060512-150254
Beatty, 2014, Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol. Res., 2, 112, 10.1158/2326-6066.CIR-13-0170
Bollino, 2017, Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy, Transl. Res., 187, 32, 10.1016/j.trsl.2017.06.003
Bryceson, 2006, Activation, coactivation, and costimulation of resting human natural killer cells, Immunol. Rev., 214, 73, 10.1111/j.1600-065X.2006.00457.x
Burgess-Beusse, 2002, The insulation of genes from external enhancers and silencing chromatin, Proc. Natl. Acad. Sci. USA, 99, 16433, 10.1073/pnas.162342499
Carlsten, 2015, Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications, Front. Immunol., 6, 266, 10.3389/fimmu.2015.00266
Chang, 2013, A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells, Cancer Res., 73, 1777, 10.1158/0008-5472.CAN-12-3558
Cheng, 2013, NK cell-based immunotherapy for malignant diseases, Cell. Mol. Immunol., 10, 230, 10.1038/cmi.2013.10
Childs, 2015, Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens, Nat. Rev. Drug Discov., 14, 487, 10.1038/nrd4506
Chowdhury, 1998, Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity, Proc. Natl. Acad. Sci. USA, 95, 669, 10.1073/pnas.95.2.669
Denman, 2012, Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells, PLoS ONE, 7, e30264, 10.1371/journal.pone.0030264
Dhar, 2018, NKG2D and its ligands in cancer, Curr. Opin. Immunol., 51, 55, 10.1016/j.coi.2018.02.004
Dolstra, 2017, Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients, Clin. Cancer Res., 23, 4107, 10.1158/1078-0432.CCR-16-2981
Eagle, 2007, Promiscuity and the single receptor: NKG2D, Nat. Rev. Immunol., 7, 737, 10.1038/nri2144
Fesnak, 2016, Engineered T cells: the promise and challenges of cancer immunotherapy, Nat. Rev. Cancer, 16, 566, 10.1038/nrc.2016.97
Figueroa, 2015, Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy, Int. Rev. Immunol., 34, 154, 10.3109/08830185.2015.1018419
Garrity, 2005, The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure, Proc. Natl. Acad. Sci. USA, 102, 7641, 10.1073/pnas.0502439102
Geller, 2011, Use of allogeneic NK cells for cancer immunotherapy, Immunotherapy, 3, 1445, 10.2217/imt.11.131
Geller, 2011, A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer, Cytotherapy, 13, 98, 10.3109/14653249.2010.515582
Giudice, 2008, Genetic modification of human embryonic stem cells for derivation of target cells, Cell Stem Cell, 2, 422, 10.1016/j.stem.2008.04.003
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134
Guillerey, 2016, Targeting natural killer cells in cancer immunotherapy, Nat. Immunol., 17, 1025, 10.1038/ni.3518
Handgretinger, 2016, Exploitation of natural killer cells for the treatment of acute leukemia, Blood, 127, 3341, 10.1182/blood-2015-12-629055
Hassan, 2008, Mesothelin targeted cancer immunotherapy, Eur. J. Cancer, 44, 46, 10.1016/j.ejca.2007.08.028
Hermanson, 2015, Utilizing chimeric antigen receptors to direct natural killer cell activity, Front. Immunol., 6, 195, 10.3389/fimmu.2015.00195
Hermanson, 2016, Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer, Stem Cells, 34, 93, 10.1002/stem.2230
Ho, 2002, Costimulation of multiple NK cell activation receptors by NKG2D, J. Immunol., 169, 3667, 10.4049/jimmunol.169.7.3667
Imai, 2005, Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells, Blood, 106, 376, 10.1182/blood-2004-12-4797
Klingemann, 2016, Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells, Front. Immunol., 7, 91, 10.3389/fimmu.2016.00091
Knorr, 2013, Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy, Stem Cells Dev., 22, 1861, 10.1089/scd.2012.0608
Knorr, 2013, Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy, Stem Cells Transl. Med., 2, 274, 10.5966/sctm.2012-0084
Koehl, 2015, Advances in clinical NK cell studies: Donor selection, manufacturing and quality control, OncoImmunology, 5, e1115178, 10.1080/2162402X.2015.1115178
Koneru, 2015, IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo, OncoImmunology, 4, e994446, 10.4161/2162402X.2014.994446
Kwon, 2016, Stepwise phosphorylation of p65 promotes NF-κB activation and NK cell responses during target cell recognition, Nat. Commun., 7, 11686, 10.1038/ncomms11686
Lanier, 2008, Up on the tightrope: natural killer cell activation and inhibition, Nat. Immunol., 9, 495, 10.1038/ni1581
Lanier, 1989, Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells, Nature, 342, 803, 10.1038/342803a0
Liu, 2018, Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity, Leukemia, 32, 520, 10.1038/leu.2017.226
Long, 2008, Negative signaling by inhibitory receptors: the NK cell paradigm, Immunol. Rev., 224, 70, 10.1111/j.1600-065X.2008.00660.x
Long, 2013, Controlling natural killer cell responses: integration of signals for activation and inhibition, Annu. Rev. Immunol., 31, 227, 10.1146/annurev-immunol-020711-075005
Love, 2010, ITAM-mediated signaling by the T-cell antigen receptor, Cold Spring Harb. Perspect. Biol., 2, a002485, 10.1101/cshperspect.a002485
Maude, 2015, CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Blood, 125, 4017, 10.1182/blood-2014-12-580068
Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974
Moriarity, 2013, Modular assembly of transposon integratable multigene vectors using RecWay assembly, Nucleic Acids Res., 41, e92, 10.1093/nar/gkt115
Morvan, 2016, NK cells and cancer: you can teach innate cells new tricks, Nat. Rev. Cancer, 16, 7, 10.1038/nrc.2015.5
Nakajima, 1999, Activating interactions in human NK cell recognition: the role of 2B4-CD48, Eur. J. Immunol., 29, 1676, 10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y
Ng, 2008, A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies, Nat. Protoc., 3, 768, 10.1038/nprot.2008.42
Ni, 2011, Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms, J. Virol., 85, 43, 10.1128/JVI.01774-10
Ni, 2013, Hematopoietic and nature killer cell development from human pluripotent stem cells, Methods Mol. Biol., 1029, 33, 10.1007/978-1-62703-478-4_3
Ni, 2014, Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo, Stem Cells, 32, 1021, 10.1002/stem.1611
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849
Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci. Transl. Med., 9, eaaj2013, 10.1126/scitranslmed.aaj2013
Ramos, 2016, CAR-T Cell Therapy for Lymphoma, Annu. Rev. Med., 67, 165, 10.1146/annurev-med-051914-021702
Romee, 2016, Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia, Sci. Transl. Med., 8, 357ra123, 10.1126/scitranslmed.aaf2341
Rosen, 2004, A Structural basis for the association of DAP12 with mouse, but not human, NKG2D, J. Immunol., 173, 2470, 10.4049/jimmunol.173.4.2470
Sakamoto, 2015, Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer, J. Transl. Med., 13, 277, 10.1186/s12967-015-0632-8
Sivori, 2000, 2B4 functions as a co-receptor in human NK cell activation, Eur. J. Immunol., 30, 787, 10.1002/1521-4141(200003)30:3<787::AID-IMMU787>3.0.CO;2-I
Smyth, 2005, Activation of NK cell cytotoxicity, Mol. Immunol., 42, 501, 10.1016/j.molimm.2004.07.034
Song, 2011, In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB), Cancer Res., 71, 4617, 10.1158/0008-5472.CAN-11-0422
Song, 2013, Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition, Hum. Gene Ther., 24, 295, 10.1089/hum.2012.143
Teachey, 2016, Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia, Cancer Discov., 6, 664, 10.1158/2159-8290.CD-16-0040
Themeli, 2015, New cell sources for T cell engineering and adoptive immunotherapy, Cell Stem Cell, 16, 357, 10.1016/j.stem.2015.03.011
Töpfer, 2015, DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy, J. Immunol., 194, 3201, 10.4049/jimmunol.1400330
Wilber, 2007, Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer, Stem Cells, 25, 2919, 10.1634/stemcells.2007-0026
Woll, 2009, Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity, Blood, 113, 6094, 10.1182/blood-2008-06-165225
Xie, 2014, Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac, Genome Res., 24, 1526, 10.1101/gr.173427.114
Yahata, 2007, cHS4 insulator-mediated alleviation of promoter interference during cell-based expression of tandemly associated transgenes, J. Mol. Biol., 374, 580, 10.1016/j.jmb.2007.09.054
Yang, 2016, Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors, Cancer Immunol. Res., 4, 215, 10.1158/2326-6066.CIR-15-0118
Zhang, 2011, Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells, Cancer Res., 71, 2066, 10.1158/0008-5472.CAN-10-3200